Moreover, treatment with a MARCKS-inhibiting peptide suppresses lung cancer growth and metastasis in vivo and enhances the sensitivity of erlotinib in lung cancer cells, particularly those tumors with sustained activation of phosphoinositide 3-kinase/AKT signaling [63]. This evidence concerns the gene AKT1 and lung cancer.